Celcuity To Participate in Jefferies Global Healthcare Conference
June 03, 2024 16:01 ET
|
Celcuity Inc.
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
May 30, 2024 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity Announces Pricing of Underwritten Common Stock Offering
May 30, 2024 07:36 ET
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
May 30, 2024 07:00 ET
|
Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
May 15, 2024 16:01 ET
|
Celcuity Inc.
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
May 08, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Orion Group Interim Report January–March 2024
April 25, 2024 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EEST Orion Group Interim Report January–March 2024 Net sales totalled EUR 308.5...
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
April 18, 2024 09:11 ET
|
Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
April 18, 2024 09:00 ET
|
Oncternal Therapeutics
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
April 04, 2024 07:05 ET
|
Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...